Ardelyx (MEX:ARDX) Beneish M-Score: -2.23 (As of Jul. 02, 2026)


MEX:ARDX Ardelyx Inc MEX:ARDX
69 GF Score
Price MXN99.00
GF Value MXN195.32
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Beneish M-Score?

Ardelyx MEX:ARDX 69 Beneish M-Score is -2.23 as of Jul. 02, 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN195.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 829 Biotechnology companies, Ardelyx ranks worse than 54.4% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.23 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ardelyx's Beneish M-Score or its related term are showing as below:

MEX:ARDX' s Beneish M-Score Range Over the Past 10 Years
Min: -29.08   Med: -1.35   Max: 23.6
Current: -2.23

During the past 13 years, the highest Beneish M-Score of Ardelyx was 23.60. The lowest was -29.08. And the median was -1.35.


Ardelyx Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Ardelyx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Beneish M-Score Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.49 10.10 -0.69 -1.16 -2.47

Ardelyx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.84 -1.97 -2.21 -2.47 -2.23

MEX:ARDX vs AVLN, INBX, JBIO: Beneish M-Score Comparison

For the Biotechnology subindustry, Ardelyx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ardelyx's Beneish M-Score falls into.


MEX:ARDX
69GF Score
Ardelyx Inc MEX:ARDX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ardelyx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4495+0.528 * 0.9142+0.404 * 1.0251+0.892 * 1.0841+0.115 * 0.8314
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0446+4.679 * -0.059791-0.327 * 1.1199
=-2.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN1,494 Mil.
Revenue was 1703.603 + 2254.584 + 2023.897 + 1838.897 = MXN7,821 Mil.
Gross Profit was 1616.848 + 2059.24 + 1950.851 + 1605.359 = MXN7,232 Mil.
Total Current Assets was MXN6,886 Mil.
Total Assets was MXN9,098 Mil.
Property, Plant and Equipment(Net PPE) was MXN116 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN62 Mil.
Selling, General, & Admin. Expense(SGA) was MXN6,515 Mil.
Total Current Liabilities was MXN1,976 Mil.
Long-Term Debt & Capital Lease Obligation was MXN3,728 Mil.
Net Income was -678.12 + -7.328 + -17.776 + -359.242 = MXN-1,062 Mil.
Non Operating Income was 38.085 + 37.416 + 44.925 + 35.625 = MXN156 Mil.
Cash Flow from Operations was -581.32 + 377.237 + 6.696 + -477.17 = MXN-675 Mil.
Total Receivables was MXN951 Mil.
Revenue was 1516.239 + 2421.952 + 1934.395 + 1341.435 = MXN7,214 Mil.
Gross Profit was 1264.542 + 2041.043 + 1624.706 + 1168.566 = MXN6,099 Mil.
Total Current Assets was MXN6,397 Mil.
Total Assets was MXN8,392 Mil.
Property, Plant and Equipment(Net PPE) was MXN109 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN44 Mil.
Selling, General, & Admin. Expense(SGA) was MXN5,753 Mil.
Total Current Liabilities was MXN1,552 Mil.
Long-Term Debt & Capital Lease Obligation was MXN3,147 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1493.829 / 7820.981) / (950.631 / 7214.021)
=0.191003 / 0.131775
=1.4495

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(6098.857 / 7214.021) / (7232.298 / 7820.981)
=0.845417 / 0.92473
=0.9142

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6886.147 + 116.04) / 9097.623) / (1 - (6397.115 + 109.144) / 8391.831)
=0.230328 / 0.224691
=1.0251

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=7820.981 / 7214.021
=1.0841

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(44.193 / (44.193 + 109.144)) / (61.566 / (61.566 + 116.04))
=0.288208 / 0.346644
=0.8314

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(6515.263 / 7820.981) / (5752.896 / 7214.021)
=0.833049 / 0.79746
=1.0446

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((3728.333 + 1975.807) / 9097.623) / ((3146.594 + 1551.55) / 8391.831)
=0.626992 / 0.559847
=1.1199

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-1062.466 - 156.051 - -674.557) / 9097.623
=-0.059791

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ardelyx has a M-score of -2.37 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.23 mean?
Ardelyx (MEX:ARDX) has a Beneish M-Score of -2.23 as of Jul. 02, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #451 out of 829 companies in the Biotechnology industry, placing it in the top 54.4%.
Is Ardelyx's Beneish M-Score too high?
Ardelyx's current Beneish M-Score is -2.23. Based on the distribution chart, Ardelyx ranks #451 out of 829 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Beneish M-Score compare to AVLN and INBX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #451 out of 829 companies for Beneish M-Score. This places Ardelyx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ardelyx and its competitors. Ardelyx's current Beneish M-Score is -2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN195.32, compared to a current price of MXN99.00 — trading 49.3% below its estimated fair value. The current Beneish M-Score is -2.23. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Beneish M-Score is -2.23 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (MEX:ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of MXN99.00 is trading 49.3% below its estimated GF Value™ of MXN195.32. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for MEX:ARDX:

  • Beneish M-Score: -2.23
  • GF Value™: MXN195.32 vs. price of MXN99.00 (49.3% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ardelyx Business Description

Other Exchanges ARDX:USA41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score

Get the complete analysis for MEX:ARDX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN99.00
Price
MXN195.32
GF Value